Skip to main content
Luye Pharma Group Limited logo

Luye Pharma Group Limited — Investor Relations & Filings

Ticker · 2186 HKEX Manufacturing
Open in API
Filings indexed 1,503 across all filing types
Latest filing 2024-07-02 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2186

About Luye Pharma Group Limited

http://www.luye.cn

Luye Pharma Group is an international pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative medications, novel formulations, and biopharmaceutical products. The company's core strategy emphasizes advanced drug delivery systems, including microspheres, liposomes, and transdermal technologies, to enhance therapeutic efficacy and patient compliance. Luye Pharma maintains a strong focus on key therapeutic areas, particularly the Central Nervous System (CNS). Its portfolio includes proprietary products such as Roxinlin® (Toludesvenlafaxine extended-release tablets) and various long-acting injectable antipsychotic formulations, positioning the group as a global pharmaceutical enterprise.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 June 2024. It details movements in authorized share capital, issued shares, treasury shares, convertibles, and confirms compliance with listing rules. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting monthly share capital and securities movements. It does not contain financial statements, earnings data, or management discussion. It is not an annual or interim report, earnings release, or investor presentation. It is a regulatory filing reporting share capital movements and confirmations as required by listing rules. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (8314 characters) and detailed content support this classification with high confidence.
2024-07-02 English
Monthly Return of Equity Issuer on Movements in Securities
Regulatory Filings Classification · 100% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 June 2024. It details movements in authorised/registered share capital, issued shares, treasury shares, share options, and confirms compliance with listing rules. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting monthly share capital and shareholding movements. It does not contain financial statements, earnings data, or management discussion. It is not an announcement of a report publication but a regulatory filing of share capital movements and confirmations. Therefore, it fits best under Regulatory Filings (RNS).
2024-07-02 English
VOLUNTARY ANNOUNCEMENT - THE MANUFACTURING FACILITY OF PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSION (LY03010) HAS PASSED PAI BY U.S. FDA WITH NO FDA-483
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Luye Pharma Group Ltd. regarding the successful passing of a Pre-Approval Inspection (PAI) by the U.S. FDA for their manufacturing facility related to a drug product. It discusses regulatory milestones, the NDA review process, and future commercialization plans. The document is relatively short (4371 characters) and serves as an announcement of a regulatory event rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed data typical of annual or interim reports. It also does not fit into categories like earnings release, capital update, or legal proceedings. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about FDA inspection results and drug approval progress, which does not fit more specific categories.
2024-06-27 English
Monthly Return of Equity Issuer on Movements in Securities
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 April 2024. It details movements in authorised/registered share capital, issued shares, treasury shares, share options, and confirms compliance with listing rules. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share movement information for a specific month. It does not contain financial statements, earnings data, management discussion, or audit information. It is a periodic regulatory filing focused on share capital movements and confirmations related to securities issuance and compliance. This fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2024-06-27 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 MARCH 2024
Annual Report Classification · 95% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 MARCH 2024' and contains detailed audited consolidated financial statements including profit or loss, comprehensive income, financial position, notes to the consolidated financial statements, and accounting policies. It covers the full fiscal year ended 31 March 2024 and includes comparative figures for the previous year. The length of the document is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or summary. This matches the characteristics of an Annual Report (10-K) rather than a short announcement or regulatory filing. Therefore, the document should be classified as an Annual Report (10-K). FY 2024
2024-06-24 English
VOLUNTARY ANNOUNCEMENT - JINYOUPING (ROTIGOTINE MICROSPHERES FOR INJECTION) APPROVED FOR MARKETING IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Luye Pharma Group Ltd. regarding the approval of a new drug (Jinyouping) for marketing in China. It discusses the drug's clinical trial results, therapeutic benefits, and strategic importance to the company. There are no financial statements, regulatory certifications, voting results, or management changes mentioned. The document is an announcement of a product approval and strategic update rather than a financial report or regulatory filing. It is not an Annual Report, Interim Report, Earnings Release, or any other financial or governance report. Given the content and nature, this fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-06-20 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.